Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
CNBC Stocks· Oct 29, 2026 · 11:44 AM
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 1 hour ago
Tech risk-reward turns favorable after rout, Deutsche Bank says
Investing.com
stocksabout 1 hour ago
Power bills and data centers cast rare spotlight on utilities in US midterms
Investing.com
stocksabout 1 hour ago
Anthropic's path to the Nasdaq just got a lot bumpier
Concerning projections from hyperscalers this week punished tech stocks and pushed the Nasdaq to its first three-week losing streak since March.
CNBC Stocks